MX2017007059A - Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación. - Google Patents

Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación.

Info

Publication number
MX2017007059A
MX2017007059A MX2017007059A MX2017007059A MX2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A
Authority
MX
Mexico
Prior art keywords
polypeptides
amino acid
acid sequence
modified
sequence lacking
Prior art date
Application number
MX2017007059A
Other languages
English (en)
Inventor
Krishnan Rajaraman
J Carr Francis
d jones Timothy
Fisher Richard
G E Holgate Robert
Asp Eva
Proschitsky Ming
Original Assignee
Proclara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proclara Biosciences Inc filed Critical Proclara Biosciences Inc
Publication of MX2017007059A publication Critical patent/MX2017007059A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a polipéptidos que comprenden una porción de la proteína del gen bacteriófago filamentoso 3 (g3p) suficiente para unir a y/o desagregar amiloide, esto es, la porción N1-N2 de g3p y mutantes y fragmentos de esto, en donde esa secuencia de aminoácidos del g3p ha sido modificada a través de deleción, inserción o sustitución de aminoácidos para retirar una señal de glicosilación putativa. La invención además se refiere a tales polipéptidos que son también modificados a través de sustitución adicional de aminoácidos para ser sustancialmente menos inmunogénicos que la correspondiente secuencia de aminoácidos de tipo silvestre de g3p cuando se utiliza in vivo. Los polipéptidos de la invención mantienen su capacidad de unir y/o desagregar amiloide. La invención además se relaciona con el uso de estos polipéptidos de g3p modificados en el tratamiento y/o prevención de enfermedades asociadas con el plegamiento erróneo o la desagregación amiloide.
MX2017007059A 2014-12-03 2015-12-02 Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación. MX2017007059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087052P 2014-12-03 2014-12-03
PCT/US2015/063476 WO2016090022A1 (en) 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Publications (1)

Publication Number Publication Date
MX2017007059A true MX2017007059A (es) 2018-05-02

Family

ID=55273507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007059A MX2017007059A (es) 2014-12-03 2015-12-02 Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación.

Country Status (20)

Country Link
US (2) US10722551B2 (es)
EP (1) EP3227313B1 (es)
JP (2) JP6730988B2 (es)
KR (1) KR20170085132A (es)
CN (1) CN107250154A (es)
AR (1) AR102890A1 (es)
AU (1) AU2015358504A1 (es)
BR (1) BR112017011530A2 (es)
CA (1) CA2969128A1 (es)
DK (1) DK3227313T3 (es)
EA (1) EA201791212A1 (es)
ES (1) ES2910017T3 (es)
IL (1) IL252426A0 (es)
MX (1) MX2017007059A (es)
PH (1) PH12017501004A1 (es)
PL (1) PL3227313T3 (es)
PT (1) PT3227313T (es)
SG (1) SG11201704427YA (es)
TW (1) TW201632542A (es)
WO (1) WO2016090022A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
TWI613212B (zh) 2012-10-02 2018-02-01 波克萊拉生物科技股份有限公司 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드
WO2019241628A1 (en) 2018-06-15 2019-12-19 Proclara Biosciences, Inc. General amyloid interaction motif (gaim)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2131003A1 (en) 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
BR0207945A (pt) 2001-03-08 2004-07-27 Merck Patent Ges Mit Beschroen Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
PL1853285T3 (pl) 2005-02-01 2011-08-31 Univ Ramot Sposób leczenia zapalenia związanego ze złogami amyloidowymi i zapalenia mózgu z udziałem aktywowanych komórek mikrogleju
CA2642473A1 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2007094003A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
JPWO2007114139A1 (ja) 2006-04-06 2009-08-13 文昭 内山 新規繊維状ファージによるファージディスプレイ
WO2008011503A2 (en) 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
CA2666320A1 (en) 2006-10-11 2008-04-17 Antitope Limited T cell epitope databases
WO2009143465A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method of imaging abnormal deposits or plaques
JP2012509672A (ja) 2008-11-24 2012-04-26 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 繊維状バクテリオファージを使用してパーキンソン病を処置するための方法
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
CA2829223A1 (en) 2011-03-11 2012-09-20 Beka Solomon Method for treating neurodegenerative tauopathy
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
TWI613212B (zh) 2012-10-02 2018-02-01 波克萊拉生物科技股份有限公司 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白
AU2014274253B2 (en) * 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드

Also Published As

Publication number Publication date
US20180207231A1 (en) 2018-07-26
PT3227313T (pt) 2022-04-12
JP2017538407A (ja) 2017-12-28
EA201791212A1 (ru) 2018-01-31
US20210015895A1 (en) 2021-01-21
ES2910017T3 (es) 2022-05-11
AU2015358504A1 (en) 2017-06-29
JP2020073610A (ja) 2020-05-14
EP3227313A1 (en) 2017-10-11
PL3227313T3 (pl) 2022-05-09
DK3227313T3 (da) 2022-04-19
WO2016090022A9 (en) 2016-08-25
US10722551B2 (en) 2020-07-28
TW201632542A (zh) 2016-09-16
WO2016090022A8 (en) 2017-06-22
EP3227313B1 (en) 2022-02-09
CA2969128A1 (en) 2016-06-09
WO2016090022A1 (en) 2016-06-09
KR20170085132A (ko) 2017-07-21
IL252426A0 (en) 2017-07-31
AR102890A1 (es) 2017-03-29
US11723951B2 (en) 2023-08-15
CN107250154A (zh) 2017-10-13
PH12017501004A1 (en) 2017-12-18
JP6730988B2 (ja) 2020-07-29
BR112017011530A2 (pt) 2018-03-13
AU2015358504A8 (en) 2017-07-13
SG11201704427YA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
PH12017501004A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
PH12015502585A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
PH12019500596A1 (en) Recombinant binding proteins and their use
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
PH12018500477A1 (en) Recombinant vectors comprising 2a peptide
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
WO2015048348A3 (en) Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX2017000378A (es) ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS.
WO2014204816A3 (en) Method for assessing protein identity and stability
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
MX2018002616A (es) Proteina de fusion.
WO2013006050A9 (en) Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma)
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
WO2017190032A3 (en) Therapeutic sall4 peptide
MX2022001489A (es) Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.
MX2016011174A (es) Peptidos y metodos de uso.